This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pediatrics  • Adolescent Medicine  • Pediatrics, Other  • Psychiatry  • Adolescent Psychiatry  • Child Psychiatry  • Suicide  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Benji T. Kurian, MD, MPH; Wayne A. Ray, PhD; Patrick G. Arbogast, PhD; D. Catherine Fuchs, MD; Judith A. Dudley, BS; William O. Cooper, MD, MPH

Arch Pediatr Adolesc Med. 2007;161(7):690-696.

Objective  To evaluate the effect of UK and US warnings placed in response to reports of suicidal thinking in pediatric patients receiving selective serotonin reuptake inhibitor and selective norepinephrine reuptake inhibitor antidepressants on antidepressant prescribing for children and adolescents.

Design  Interrupted time-series analysis of antidepressant prescriptions.

Setting  Tennessee's Medicaid program, January 1, 2002, through September 30, 2005.

Participants  A mean of 405 000 children and adolescents aged 2 to 17 years qualified each month.

Main Exposure  Piecewise linear regression models were used to estimate the cumulative effect of the warnings, which were considered the exposure of interest.

Main Outcome Measures  Monthly proportions of study children and adolescents who were new users of antidepressants, had discontinuity in antidepressant use, or were users of other psychotropic drugs.

Results  During the 2 years preceding the UK warning, there was no trend in the monthly proportions of new antidepressant users, with 23 new users per 10 000 persons per month. This proportion subsequently decreased 33% (95% confidence interval, 23% to 41%; P < .001) by 21 months following the UK warning. The reduction was most pronounced for the nonfluoxetine selective serotonin reuptake inhibitors and selective norepinephrine reuptake inhibitors, where initiations decreased 54% (95% confidence interval, 46% to 62%; P < .001). In contrast, new users of fluoxetine increased 60% (95% confidence interval, 9% to 135%; P = .02). There was no increase in discontinuations of antidepressants, and there was no evidence of substitution of other psychotropic drugs.

Conclusion  The regulatory warnings led to decreased use of antidepressants in children and adolescents, but the clinical and public health consequences of this change are unknown.

Author Affiliations: Departments of Psychiatry (Drs Kurian and Fuchs), Preventive Medicine (Dr Ray and Ms Dudley), Biostatistics (Dr Arbogast), and Pediatrics (Dr Cooper), Vanderbilt University School of Medicine, Nashville, Tennessee.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Persisting Decline in Depression Treatment After FDA Warnings
Libby et al.
Arch Gen Psychiatry 2009;66:633-639.
ABSTRACT | FULL TEXT  

To prescribe or not to prescribe?
Menon
Br. J. Psychiatry 2009;194:189-189.
FULL TEXT  

The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration
Ogrinc et al.
Qual Saf Health Care 2008;17:i13-i32.
ABSTRACT | FULL TEXT  

Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults
Katz et al.
CMAJ 2008;178:1005-1011.
ABSTRACT | FULL TEXT